Advertisement
Home Tags Cancer: Misc.

Tag: Cancer: Misc.

Hispanics have lower cancer incidence and death rates than non-Hispanic whites

Cancer Incidence, Mortality Lower Among Hispanics

0
Variations in cancer risk due to differences in exposure to carcinogens, screening rates, lifestyle
Nearly three-fourths of American voters support increasing federal funding for cancer research

Voters Support More Federal Funding of Cancer Research

0
AACR's new report calls for enhanced funding to further progress against cancer
Childhood cancer survivors who have had one stroke are at high risk for having another

Childhood CA Survivors Who Have Stroke at Higher Risk of Second

0
Rate is double that of people without cancer who've lived through one stroke
Vietnam veterans exposed to Agent Orange have a more than doubled risk of developing monoclonal gammopathy of undetermined significance

Agent Orange Tied to MGUS in Vietnam Vets

0
Exposed veterans have higher rates of monoclonal gammopathy of undetermined significance

August 2015 Briefing – Hematology & Oncology

0
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for August 2015. This roundup includes...
For some pediatric cancer patients with relapsed or refractory cancer

Genomic Sequencing Benefits Some Childhood Cancer Patients

0
Benefits seen for some children and young adults with relapsed or refractory cancer
Physicians whose peers were early adopters of brachytherapy for the treatment of women with early-stage breast cancer are more likely to adopt the therapy themselves

Physicians’ Peers Influence Use of New Cancer Tx Modalities

0
Exposure to peers who were early adopters of brachytherapy associated with increased use
In patients with newly diagnosed multiple myeloma

Continuous Therapy Improves Survival in Multiple Myeloma

0
Benefit seen in progression-free, overall survival compared with fixed duration of therapy
Many elderly oncology patients use complementary and alternative medications

Many Elderly Oncology Patients Taking Alternative Medicines

0
Associated with polypharmacy, vision impairment, and urologic comorbidities
Daratumumab monotherapy has a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma in a phase 1-2 trial. The results of the study were published online Aug. 26 in the New England Journal of Medicine.

Daratumumab Monotherapy Promising for Multiple Myeloma

0
Findings in a phase 1-2 study of patients with relapsed myeloma or relapsed/refractory myeloma